Document |
Document Title |
WO/2022/168846A1 |
A barrier function improver which contains methylhesperidin as an active ingredient, and a barrier function improver composition which contains said barrier function improver and a pharmaceutically acceptable carrier.
|
WO/2022/162161A1 |
The present invention provides novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds...
|
WO/2022/162992A1 |
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease. Examples of the pre...
|
WO/2022/162154A1 |
The present invention provides novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds...
|
WO/2022/162153A1 |
The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compoun...
|
WO/2022/162157A1 |
The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compoun...
|
WO/2022/157233A1 |
The present invention relates to compounds of the following formula (I): as well as their preparation process; their use in cosmetic or dermatological applications, in particular for the treatment and/or prevention of skin aging, skin pr...
|
WO/2022/156424A1 |
An amphiphilic molecular self-assembly nanodrug for tumor treatment, a preparation method therefor and a use thereof. Specifically disclosed is an amphiphilic compound, which is a conjugate of a hydrazine group-modified organic photother...
|
WO/2022/150924A1 |
Carbohydrate of Formula (A) where R1 is H and n an integer from 1 to 5, is synthesized by reacting, under heating, compound (A0) with HO-(CH2)n-CH=CH2 in the presence of an acid capable of liberating a proton, and cooling the reaction mi...
|
WO/2022/155518A1 |
The present disclosure provides, benzimidazole derivatives and antibody-drug conjugates thereof which act as STING agonists and are useful in treating various diseases such as cancer.
|
WO/2022/149074A1 |
Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulantselected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and/orimmunostimulant may be present as a pharmaceutically a...
|
WO/2022/146137A1 |
The present invention relates to a compound, represented by formula (I): (I) wherein a) R, R1, R2 and R4 are independently of one another a hydrogen 0 atom or a C1-C6 linear or branched alkyl, or a C1-C6 linear or branched alkenyl, or a ...
|
WO/2022/135319A1 |
The present invention relates to a method for the automatic preparation of a fondaparinux sodium pentasaccharide intermediate. The method is based on an automatic preparation device. According to the method, automatic preparation of thre...
|
WO/2022/133480A1 |
The present invention provides AHR agonists, composites thereof, and methods of using the same.
|
WO/2022/130238A1 |
A new process for the synthesis of amide derivatives of 8-hydroxypenicillanic acid is described, more specifically starting from amide derivatives of the 6-aminopenicillanic nucleus protected as tert-butylcarbamate.
|
WO/2022/131129A1 |
A purpose of the present invention is to provide a xanthohumol glycoside in which a sugar chain constructed from two or more hexoses is bonded to xanthohumol and a method for producing the same, a xanthohumol glycoside in which one hexos...
|
WO/2022/125956A1 |
Provided herein are lipid A molecules engineered from Moritella lipopolysaccharides and uses thereof.
|
WO/2022/125735A1 |
The disclosure provides processes for preparing the compound of formula (VIII) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIII) are also provided.
|
WO/2022/106703A1 |
The present invention provides zwitterionic oligosaccharides, in particular fragments of the surface polysaccharides from Shigella sonnei and Shigella sonnei conjugates comprising them. The present invention also provides protected disac...
|
WO/2022/109335A1 |
The present disclosure provides antibody-drug conjugate structures, which include a cleavable linker that links the antibody to the drug and has a first enzymatically cleavable moiety and a second enzymatically cleavable moiety which inc...
|
WO/2022/102652A1 |
The present invention provides a novel compound, which has a TLR4 activating effect and is usable as an immune activator or adjuvant in vaccine or allergen immunotherapy, or a pharmaceutically acceptable salt thereof. A compound repres...
|
WO/2022/094711A1 |
Disclosed is a process of preparation of a compound of formula 13, and intermediates prepared and used in the preparation of the compound of formula 13.
|
WO/2022/094913A1 |
Disclosed are a sialic acid Neu5Ac derivative, and a preparation method therefor and the use thereof. The structure of the derivative is as shown in (VII)I below, wherein R1 is selected from hydroxyl, methoxy, or substituted methoxy; R2 ...
|
WO/2022/099078A1 |
The present disclosure provides methods for making glycosylated cannabinoids including methods using recombinant host cells comprising a pathway capable of producing a cannabinoid and a heterologous nucleic acid that encodes a UDP-glycos...
|
WO/2022/094932A1 |
A novel coronavirus detection test strip, and a preparation method and a use method therefor. The test strip comprises a lining plate (1), and a sample pad (2), a gold labeling pad (3), a detection pad (4) and a water absorption plate (5...
|
WO/2022/092970A1 |
The present invention relates to a compound isolated from Antarctica-derived fungi and a composition comprising same, and more particularly, to a novel compound isolated from Acremonium sp. SF-7394, an anti-inflammatory, anti-cancer or a...
|
WO/2022/087107A1 |
Compositions for treating an ischemic condition in a subject may include hexosamine D-mannosamine (ManN). Methods may include administering to the subject in need thereof an effective amount of ManN. The administration may be effective t...
|
WO/2022/078487A1 |
The present disclosure provides a zolinose compound represented by formula (I), a preparation method therefor and a use thereof, wherein definitions of substituents are provided in the description. The zolinose compound has application p...
|
WO/2022/075836A1 |
Provided are methods and systems for the production of alkyl polyglucoside. The methods and systems provide for improved purification that results in reduced produce degradation.
|
WO/2022/065895A1 |
The present invention relates to a novel salt of an empagliflozin derivative and a hydrate of the salt, which have a relatively higher fusion point, solubility and melting point than those of empagliflozin, which is a drug developed as a...
|
WO/2022/061168A1 |
E-selectin ligands which are useful for the synthesis of E-selectin ligand-bearing carriers,wherein said E-selectin ligand-bearing carriers are directly or indirectly linked to or associated with at least one therapeutic agent, diagnosti...
|
WO/2022/040487A1 |
This disclosure provides triptolide-conjugates, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, as well methods of using such compounds in the treatment of conditions/diseases, suc...
|
WO/2022/034429A1 |
The present invention relates to a synthesis process of β-6-sulfoquinovosyl-diacylglycerols. In particular, said process is for the synthesis of the compounds 1,2-O-distearoyl-3-O-(β- sulfoquinovosyl)-R/S-glycerol, 1,2-O-distearoyl-3-O...
|
WO/2022/034582A1 |
Described herein are novel, macrophage targeting drug conjugates. The macrophage targeting drug conjugates comprise a drug moiety, a mannose moiety, and a linker connecting the drug moiety and the mannose moiety. The linker may comprise ...
|
WO/2022/029704A1 |
The present invention relates to a process for the preparation of a compound of formula (I) and to novel intermediates of the synthesis, wherein X is hydrogen, bromine or iodine; R1 is a protecting group, R2 is hydrogen or a protecting g...
|
WO/2022/030577A1 |
The present invention provides a sophorolipid (SL)-containing composition having excellent handleability, and a production method therefor. An SL-containing composition according to the present invention has the following properties: (A)...
|
WO/2022/026431A1 |
A method using an increase of agitation energy per unit volume in the crystallization of amorphous solid or spray dried solid starting material is provided. This method improves the efficiency of crystallization process and corresponding...
|
WO/2022/024067A1 |
This application relates to efficient methods for the synthesis of ascarylose and its derivatives. A method for the production of ascarylose includes: providing, as a feedstock, a 1-O-substituted rhamnose; forming a mono-sulfonate ester ...
|
WO/2022/016755A1 |
The present invention relates to the technical field of chemistry and medicines. Disclosed are a trehalose derivative and carbohydrate antigen conjugate, and a preparation method therefor and an application thereof. According to the pres...
|
WO/2022/020295A1 |
The present disclosure provides compounds for the treatment of medical disorders caused by bacteria, in particular aprosamine derivatives for the treatment of bacterial infections.
|
WO/2022/017844A1 |
The invention relates to new rhamnolipid esters, to a method of their production and also to the use of the rhamnolipid ester as cosmetic additives.
|
WO/2022/013430A1 |
The present invention relates to new glycolipids derivatives of Formula (I) and their use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels. The present invention further relat...
|
WO/2022/012630A1 |
Disclosed is a method for preparing a C-nucleoside compound represented by formula (III), or a salt thereof. The present method has a high reaction yield, is simple to operate, uses a single metal reagent, has stable reaction temperature...
|
WO/2022/013500A1 |
The present invention relates to a method for obtaining surfactant compositions from raw plant materials. These surfactant compositions contain a mixture of n-alkyl glycosiduronic acid(s) and/or n-alkenyl glycosiduronic acid(s) and n-alk...
|
WO/2022/010252A1 |
The present invention relates to an alkylene-oxide-added polyol composition, a polyurethane using same, and a hot-melt adhesive comprising same, and, more specifically, to an alkylene oxide-added polyol composition, a polyurethane using ...
|
WO/2022/007136A1 |
A composition, comprising a compound represented by formula I or a pharmaceutical salt, dimer or trimer thereof, and a tyrosine kinase activity inhibitor. On the basis of an inhibitory effect of the tyrosine kinase activity inhibitor tar...
|
WO/2022/008527A1 |
The invention relates to a polymeric micelle comprising a block copolymer comprising a polyethylene glycol (PEG) hydrophilic block and a hydrophobic block, and a compound according to formula (I) or formula (III) encapsulated within said...
|
WO/2022/004873A1 |
The present invention provides: a derivative that is of curcumin monoglucuronide, that has excellent solubility and chemical stability, and that can be provided as a medicinal drug; and a method for producing said derivative. A salt th...
|
WO/2022/003305A1 |
The present invention relates to a process for preparing an alkyl polyglucoside by enzymatic catalysis, using sucrose or an analogue thereof as substrate and making it possible to obtain a large diversity of alkyl polyglucosides in terms...
|
WO/2021/262043A1 |
Components of bioluminescent systems are widely used reagents for a large number of assays, including diagnostic systems, quality control systems, drug trial systems and the like. The present group of inventions discloses components of t...
|